The question
Not “which antiplatelet should be prescribed?” but the narrower, safer workflow question of whether CYP2C19-related suitability should be reviewed before treating clopidogrel as straightforward.
Case Study
Clopidogrel and CYP2C19 review, explained as a governed workflow.
This example shows how QbitQure can support a more structured, accountable personalised-medicine workflow around a practical question: should CYP2C19-related suitability be reviewed when clopidogrel is under consideration?
Why it is a good example
It is a clinically familiar use case, tied to accepted PGx guidance, and well suited to a human-in-the-loop review model.
Important boundary
This case study is informational and product-development focused. It is not treatment advice and should not be used as a prescribing instruction.
Why this use case matters
Clopidogrel is a familiar and clinically recognizable example of pharmacogenomics becoming relevant to real treatment pathways. That makes it a useful public demonstration of personalised medicine in workflow form.
What QbitQure shows today
A governed review pathway can sit on top of structured case data, preserve provenance, and carry an explainable antiplatelet review through to sign-off and final outcome.
What it does not claim
This is not a prescribing engine, emergency antiplatelet tool, or full longitudinal EHR review. It is an early-stage workflow and review platform demonstration.
Workflow story
What QbitQure is trying to do in this scenario
The platform is not trying to make an ungoverned final decision. It is trying to make the review process clearer: gather the case, preserve the source data, structure it, attach an explainable clopidogrel pathway review, and carry that through to sign-off and final outcome.
Step 1
Start with a focused antiplatelet question
QbitQure begins with a clear review question so the workflow stays anchored to a specific clinical concern rather than a vague data search.
Step 2
Preserve provenance and structure the case
The original case context is retained, then shaped into standards-aware data so later review can be traced back to its source.
Step 3
Apply a bounded CYP2C19 review prompt
The platform can then frame a clopidogrel review around visible CYP2C19 signals, missing genotype information, and clearly stated unknowns.
Step 4
Keep human sign-off explicit
Review ownership, GP sign-off, and final outcome remain visible so the workflow supports clinician judgement instead of bypassing it.
The practical output
A suitability review prompt, not a black-box answer.
In this workflow, QbitQure can surface a few bounded things: whether clopidogrel appears to raise a CYP2C19 review question, whether genotype information looks missing, whether reduced activation may need attention, and what sign-off state the case is in.
That means the value is not just the pathway logic itself. It is the combination of logic, provenance, governance, and outcome recording in one place.
Supporting references
QbitQure uses this example because it shows how a clinically recognizable question can be turned into a transparent, bounded, human-reviewed workflow rather than a vague AI claim.
Collaboration
Interested in the platform direction behind this case study?
If you are interested in personalised medicine, pharmacogenomics workflows, translational health technology, or future computational medicine strategy, QbitQure is open to thoughtful discussion and collaboration.